These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
    Author: Fraaij PL, Neubert J, Bergshoeff AS, van Rossum AM, Hartwig NG, Schroten H, Korn K, Burger DM, de Groot R, Niehues T.
    Journal: Antivir Ther; 2004 Apr; 9(2):297-9. PubMed ID: 15134193.
    Abstract:
    We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of children infected with NRTI-resistant HIV-1. The combination of lopinavir/ritonavir and efavirenz suppressed HIV-1 levels for a prolonged period and resulted in a significant increase in CD4+ T cell numbers despite an extensive prior treatment with NRTI (>4 years). Observed side effects were transient with the exception of dyslipidaemia.
    [Abstract] [Full Text] [Related] [New Search]